BIOSPECIMENS ACCESSIONING AND PROCESSING SHARED RESOURCE PROJECT SUMMARY The Mayo Clinic research enterprise includes several well-established, NIH-supported research programs and centers, including the NCI-designated comprehensive Mayo Clinic Cancer Center (MCCC) and the Mayo Clinic Center for Individualized Medicine (CIM) whose goal is to move advances in genomics, epigenomics, transcriptomics, and metabolomics into the clinic as rapidly as possible. The Biorepository Program, 1 of the 7 infrastructure programs overseen by CIM, is enterprise-wide, with all activities represented at Mayo Clinic Rochester, Mayo Clinic Florida, and Mayo Clinic Arizona. The mission of the Biorepository Program is to provide world-class biorepositories and state-of-the-art biospecimen processing and storage with a focus on quality and service. The Biorepository Program's Biospecimens Accessioning and Processing (BAP) laboratory provides pre-analytical processing and storage of any type of biospecimen to support the eventual translation of scientific discoveries into clinical practice. In addition to its role as an MCCC Shared Resource, BAP provides extensive support to a number of cancer-related Specialized Programs of Research Excellence (SPOREs); clinical trial groups, such Alliance and Academic and Community Cancer Research United (ACCRU); multisite/consortium groups; and the American Cancer Society. BAP's electronic biospecimen accessioning and tracking, combined with a broad range of specimen processing services, have created a very powerful, synergistic resource that is invaluable for supporting the Basic Science, Clinical and Translational Research and Population Sciences Programs of the MCCC. BAP is also a great biospecimen resource for MCCC members. There are 2 large cohorts that the BAP lab stores in the biorepository: 1) The Mayo Clinic Biobank is an institutional resource that contains biological specimens from 50,000 volunteers from our clinics who also provided self-reported risk-factor data, access to the clinical data in their medical records, and consent to participate in unspecified research studies. Today, over 1.25 million aliquots have been prepared and stored in a robotic freezer for future use. Data and specimens have been requested by close to 90 Mayo Clinic investigators from all 3 sites for more than 200 approved projects. On average, two-thirds of the PIs requesting specimens are MCCC members; 2) The All of Us Research Program Biobank is an NIH Precision Medicine Initiative; in 2016, BAP was tapped to be the central biobank for processing and storing biospecimens from 1 million participants. The 34 million specimens, together with their corresponding data, will be another good resource for the research of MCCC members. This award, together with institutional support, has allowed BAP to expand in capacity, capability, automation, and space, which will be a great benefit to MCCC members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113588
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227

Showing the most recent 10 out of 1129 publications